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Abstract 
Purpose: The use of taxanes to treat node-positive (N+) breast cancer patients is associated 
with heterogeneous benefits as well as with morbidity and financial costs. This study aimed to 
assess the economic impact of using gene-expression profiling to guide decision-making 
about chemotherapy, and to discuss the coverage/reimbursement issues involved. 
 
Methods: Retrospective data on 246 patients included in a randomized trial (PACS01) were 
analyzed. Tumours were genotyped using DNA microarrays (189-gene signature), and 
patients were classified depending on whether or not they were likely to benefit from 
chemotherapy regimens without taxanes. Standard anthracyclines plus taxane chemotherapy 
(strategy AT) was compared with the innovative strategy based on genomic testing (GEN). 
Statistical analyses involved bootstrap methods and sensitivity analyses. 
 
Results: The AT and GEN strategies yielded similar 5-year metastasis-free survival rates. In 
comparison with AT, GEN was cost-effective when genomic testing costs were less than 
2,090€. With genomic testing costs higher than 2,919 euros, AT was cost-effective. 
Considering a 30% decrease in the price of docetaxel (the patent rights being about to expire), 
GEN was cost-effective if the cost of genomic testing was in the 0€-1,139€ range; whereas 
AT was cost-effective if genomic testing costs were higher than1,891 euros. 
 
Conclusions: The use of gene-expression profiling to guide decision-making about 
chemotherapy for N+ breast cancer patients is potentially cost-effective. Since genomic 
testing and the drugs targeted in these tests yield greater well-being than the sum of those 
resulting from separate use, questions arise about how to deal with extra-well being in 
decision-making about coverage/reimbursement. 
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Introduction 
During the last few years, pharmacogenomic research has hold great promises for optimizing 
the clinical management of cancer patients. Although the pace of development of genomic 
tests is  slower than it was expected to be a few years ago and only a few genomic tests have 
been marketed so far, issues about insurance coverage and reimbursement have been recently 
discussed in the context of increasing concern about healthcare costs [1,2].  
The need for cost-effectiveness analyses has been stressed by many authors [3,4]  since these 
studies provide third-party payers (private and public health insurance systems) with 
evidence-based estimates of economic impact on which to base decision-making about 
coverage/reimbursement [5, 6]. However, genomic testing of drug response raises specific 
questions relating to coverage/reimbursement. Since genomic testing and the drugs targeted in 
these tests should yield greater patients‟ well-being (due to increased effectiveness and/or 
fewer side-effects) than the sum of those resulting from separate use, questions arise as to 
how extra well-being should be assessed and handled in coverage/reimbursement decision-
making processes. While some authors have pointed out the complementarity existing 
between genomic testing and the drugs targeted in the context of regulatory approval [1,7], 
complementarity has not yet been discussed to our knowledge in the context of 
coverage/reimbursement decisions. 
In the field of breast cancer, several studies showed that gene-expression profiling could 
provide a useful tool for defining tumor subtypes and predicting patients‟ responses to 
treatment [8,9,10]. Breast cancer is the most common female cancer occurring in 
industrialized countries, and is still the main cause of cancer-related death among European 
women [11]. The ability of adjuvant chemotherapy to improve the prognosis of breast cancer 
and prolong survival has been clearly established [12], and anthracycline-based chemotherapy 
has been the standard adjuvant treatment for breast cancer patients during the last decade. 
More recently, taxanes (docetaxel and paclitaxel) were introduced into the therapeutic 
sequence in the case of axillary lymph node-positive (N+) patients, in addition to regimens 
based on anthracylines. The majority of N+ patients in France are currently undergoing 
regimens based on both anthracyclines and taxanes [13]. However, the limited benefit of 
taxanes in first line chemotherapy [14-18] suggest that many patients probably do not benefit 
from the adjunction of taxanes [19]. In this context, genomic testing might improve the 
effectiveness of treatments by determining which
 
patients are likely to benefit most from them, 
thus avoiding unnecessary therapy and ensuring more cost-effective care [1,20-22].  
To investigate these issues, a cost-effectiveness analysis was conducted in which the impact 
of tumour gene expression profiling was assessed in patients with early N+ breast cancer 
treated with adjuvant chemotherapy [23,24]. More specifically, the aim of the study was to 
assess the cost-effectiveness of genomic testing used to identify whether or not N+ breast 
cancer patients are likely to benefit from a regimen based on anthracyclines alone, i.e. without 
the adjunction of taxanes. While an ongoing prospective multicentre study (involving three 
French cancer centers) is focusing on the clinical benefits associated with routine use of gene 
expression profiling, the present study is based on the currently available retrospective data. 
This study presents findings on the expected impact of gene expression profiling in terms of 
both health outcomes and costs of care, and discusses some issues relating to the 
coverage/reimbursement of genomic testing. 
Material and methods 
The data set 
The present cost-effectiveness analysis was performed using on data from the PACS 01 
randomized clinical trial [16] carried out by a network of French national cancer centers 
(FNCLCC). In this trial, anthracyline-based chemotherapy (6 cycles of FEC 100) was 
compared with a combined anthracycline and taxane regimen (3 FEC 100 followed by 3 
cycles of docetaxel) in the adjuvant setting in 1999 N+ breast cancer patients. In addition to 
the clinical data, individual economic data on the patients‟ hospital care (surgery, 
chemotherapy and other drugs, laboratory investigations, length of hospital stay, etc;) were 
available [25].  
Tumour genotyping was performed (by Ipsogen, Marseilles, France, http://www.ipsogen.com/) 
using DNA microarrays from frozen samples collected from 246 patients enrolled in the 
PACS 01 clinical trial. Among these 246 patients, 128 received a chemotherapy regimen 
based on anthracylines alone and 118 received a combined anthracyline plus taxane regimen. 
We recently described a 189-gene expression signature predictive of metastatic relapse after 
adjuvant anthracycline-based chemotherapy without taxane [24]. This signature was identified 
in a learning set of 323 patients and subsequently validated in an independent set of 175 
patients. Based on this signature, the 246 patients were retrospectively categorized into a good 
prognosis group (patients likely to benefit from a regimen based on anthracyclines alone) and 
a poor prognosis group (patients unlikely to benefit from a regimen without taxane). In all, 
197 out of the 246 patients were identified as having a good prognosis (105 of the patients in 
this group received an anthracycline-based chemotherapy and 92 received an anthracycline 
plus taxane regimen), and 49 were identified as having a poor prognosis (anthracycline-based 
chemotherapy and anthracycline plus taxane chemotherapy administered to 23 and 26 patients, 
respectively). 
Specification of strategies 
In the present cost-effectiveness analysis, the current standard treatment strategy for N+ breast 
cancer patients [16] was compared with the innovative strategy involving gene expression 
profiling to guide decision-making about chemotherapy (Figure 1). More specifically, the 
following strategies were compared: 
1. The AT strategy: all patients received a regimen of 3 cycles of anthracyclines followed by 
three cycles of docetaxel (3 FEC 100 + 3 docetaxel), which is the standard treatment for N+ 
patients in France [16]. 
2. The GEN strategy: all the patients‟ tumors were genotyped, and the chemotherapy received 
by patients depended on the results of the gene-expression profiling: 6 cycles of 
anthracycline-based chemotherapy (FEC100) in good prognosis patients, and anthracyline 
plus taxane chemotherapy (3 FEC 100 + 3 docetaxel) in poor prognosis patients.  
Since some patients were included in both AT and GEN strategies, comparisons between 
strategies in terms of effectiveness and costs required specific statistical methods: these are 
described in the “Statistical Analysis” Section.  
Effectiveness of strategies 
The endpoint adopted to assess the effectiveness of these strategies was metastasis-free 
survival (MFS), as this was the clinical outcome used to identify the gene expression patterns 
correlated with patients‟ prognosis. MFS was calculated from the date of diagnosis up to the 
date of first distant metastasis. Patients who did not have any metastatic relapse were 
censored. Survival rates and mean survival times were calculated using the Kaplan-Meier 
method. The variance estimator of the survival times was calculated using bootstrap methods, 
since no simple expression for this parameter is available. Bootstrap tests were also conducted 
to determine the equality of mean survival times (for further details, see the “Statistical 
analysis” Section). 
Treatment Costs  
The costs included in the analysis were from the healthcare provider perspective, taking only 
medical costs into account. As with the effectiveness data, the cost data were obtained on the 
246 patients included in the PACS 01 trial [25]. The cost analysis was performed using the 
micro-costing method, which consisted in measuring resource utilization in physical 
quantities, combined with a monetary valuation using unit cost data [6]. Physical quantities 
involved in medical resource utilization were collected prospectively alongside the PACS 01 
trial.  
The following resource items were collected for calculating costs:  
Hospital stays: inpatient stays (number of days) and day clinic visits (number of visits) 
Pharmacy: quantities of drugs administered (chemotherapy, antibiotics, Filgrastim G-CSF, 
anti-emetics, etc.) 
Laboratory: the tests and medical investigations specified in the clinical protocol (including 
pre-treatment tests). 
Surgical procedure: mastectomy or breast conserving surgery (lumpectomy). 
Monetary values expressed in euros (€) were attributed to all physical quantities consumed 
(based on the current rate of exchange, 1€ is worth about 1.30US$). Because of the well-
known differences existing between hospital charges and real costs [26], especially in the 
context of a publicly funded health care system such as the French one, hospital charges were 
not used to assess the costs associated with hospitalization. Instead of hospital charges, “real 
cost” per diem of hospitalizations and outpatient visits were used, based on the detailed data 
on annual expenditures that were routinely collected at a French cancer center‟s analytic 
accounting system (Institut Paoli-Calmettes). These costs included that of the staff involved, 
depreciation of equipment (using a depreciation rate of 20%), consumable supplies, and food 
costs. A 20% overhead rate was added to these hospital costs to account for the administrative 
resources used [6]. Drug prices were the purchase prices negotiated at national level by the 
Federation of French Cancer Hospitals. Costs of laboratory tests, diagnostic tests and surgical 
acts were based on the tariffs applied by the French national health insurance system.  
Since the clinical trial involved collecting economic data from randomization in the PACS 01 
trial up to the end of chemotherapy, the total costs of the treatments were calculated only 
during this period of time. This limitation can be partly justified by the fact that the post-
treatment follow-up and laboratory tests conducted after completion of the treatment were 
likely to be the same, regardless of which of the two treatment strategies was used.  
Cost-effectiveness  
In most cost-effectiveness analyses, the results of comparisons between strategies of care are 
generally expressed in terms of incremental cost-effectiveness ratios (ICER), which give the 
additional cost required to reach one additional unit of effectiveness. However, as genomic 
profiling was designed to avoid over-treatment (adding taxanes) without reducing the 
effectiveness of chemotherapy [24], the cost-effectiveness analysis could be reduced to a cost-
minimization analysis once the validity of the hypothesis that the effectiveness of both 
strategies was similar had been confirmed. 
Statistical analysis 
Since some patients were included in both the AT and GEN strategies (patients having 
received anthracycline- and taxane-containing regimens and retrospectively identified as 
having a poor prognosis based on the results of gene-expression profiling), correlations 
between the data make the standard statistical methods not appropriate. To deal with this 
problem, bootstrap methods were used which consist in resampling and simultaneously 
replacing variables (costs, survival times, occurrence of events, and strategy) to preserve the 
correlations between them. This procedure was repeated a large number of times (10,000 
times in this case). Based on the variance of the survival differences and the variance of the 
costs differences thus obtained, bootstrap tests were carried out to determine the equality of 
mean survival times and the equality of average costs. Confidence intervals were calculated 
on the difference between the mean costs of the two strategies compared. 
Sensitivity analysis 
Sensitivity analyses were conducted by varying some key parameters in order to assess the 
robustness of the cost findings. Given the high likelihood that genomic testing would strongly 
affect the cost of the GEN strategy, the first key parameter tested was the cost of genomic 
testing (including preservation and transportation of the samples, RNA extraction, as well as 
the price of genomic testing, which has not yet been set). The second key parameter in the 
assessment of the AT and GEN strategies was the purchase price of docetaxel, since this drug 
will soon become available as a generic drug (patent rights expired in 2010 in the US and 
most European countries), and will therefore cost less than its brand name counterpart. These 
parameters were varied simultaneously (cost of genomic testing was taken to be in the 0€-
5,000 € range, and the price of docetaxel was taken to decrease by -10% to -60% ), and the 
difference between the costs of the two strategies (including 95% CI) was calculated.  
Results 
The clinical characteristics of the 246 patients included in this analysis are presented in Table 
1. All the patients were between 29 and 64 years of age and they all had histologically 
confirmed axillary lymph node involvement without any metastases. Among these 246 
patients, 128 received an anthracycline-based chemotherapy without taxane, and 118 received 
combined anthracycline/taxane chemotherapy. The regimen involving anthracyline consisted 
of fluorouracil 500mg/m², epirubicin 100mg/m² and cyclophosphamide 500mg/m². The 
chemotherapy regimen involving taxane consisted of three cycles of the same FEC regimen, 
followed by three cycles of docetaxel 100mg/m². The patients‟ clinical characteristics were 
well balanced between treatment groups (anthracycline vs taxane, p>0.05 in all the cases). 
Among these 246 patients, genomic testing led to identifying 197 patients (80.1%, 95%CI: 
75.1%-85.1%) as having a good prognosis, while the remaining 49 patients (19.9%, 95%CI: 
14.9%-24.9%) were found to have a poor prognosis. Since the clinical PACS 01 trial was not 
designed to assess the impact of genomic testing on patients‟ health outcomes, it emerged that 
53.3% of the patients with a good prognosis received a chemotherapy regimen without taxane 
while 47.7% received a combined anthracycline/taxane regimen. Conversely, 47.9% of the 
patients classified as having a poor prognosis received a taxane-free chemotherapy regimen, 
while 53.1% received a combined anthracycline/taxane regimen (Table 2).  
Effectiveness of therapeutic strategies 
The survival rates are summarized in Table 2. Effectiveness of strategies was calculated in 
terms of metastasis-free survival (MFS) during a median follow-up time of 60 months. The 5-
year MFS was 81.4% in the case of the AT strategy and 83.4% in that of the GEN strategy 
(p=0.34).  
Patients in the good prognosis group had similar survival times regardless of the treatment 
undergone (5-year MFS was 87.0% and 84.9%, depending on whether or not the 
chemotherapy regimen included taxanes), which suggests that these patients did not benefit 
from the adjunction of taxanes. In the poor prognosis group, the 5-year MFS was higher 
among the patients who had received taxane than among those who had not (69.2% vs 60.9%), 
although this difference was not statistically significant because of the small numbers 
involved (p=0.58).  
Treatments costs and cost-minimization analysis 
Based on the measurement of the resources individually consumed by the 246 patients 
involved in the analysis, the average treatment costs associated with the AT and GEN 
strategies are presented in Table 3, along with the proportions of the costs attributable to the 
various cost categories. Note that the treatment cost values given in Table 3 include docetaxel 
priced as a brand name drug.   
Taking only the costs incurred during the treatment period, the mean cost per patient in the 
case of the AT strategy was 12,688€ (95%CI: [12,329 ; 13,047]), where the purchase cost of 
taxanes amounted to 31.9% of the total cost. In the case of the GEN strategy, the mean cost 
per patient (not including the cost of gene expression profiling) was 10,184€ (95%CI: [9,825 ; 
10,543]), which is 19.6% lower than with the AT strategy. With cost savings of 2,504€ per 
patient (95%CI: [-2,999 ; -2,010]) without any loss of effectiveness, the GEN strategy 
therefore turned out to be preferable to the standard docetaxel-based AT strategy (p<0.001).  
Since gene expression profiling is currently performed only in clinical trials designed to 
prospectively assess patients‟ health outcomes, it is not covered by the French health 
insurance system and has therefore not been priced. Taking the cost of genomic testing into 
account yielded the results presented in Figure 2. With genomic testing costs below 2,090€ 
(including tumour sample preparation, transportation, and testing), the GEN strategy 
dominated the AT strategy as it was significantly less costly; whereas taking the costs of 
genomic testing to amount to more than 2,919€ made the strategy AT cost-effective. When 
the genomic testing costs ranged between these two values, the total cost of AT and GEN 
strategies was similar, and the two strategies were therefore equivalent. 
Since all the results presented above were based on docetaxel priced as a brand name drug, 
and since taxanes accounted for 31.9% and 7.3% of the mean cost of strategies AT and GEN, 
respectively, a sensitivity analysis was carried out on the cost of genomic testing and that of 
docetaxel (Figure 2). Since generic drugs usually cost about 30%-40% less than their brand 
name counterparts, a 30% decrease in the price of docetaxel was applied. In this case, the 
GEN strategy dominated the AT strategy when the cost of genomic testing was in the 0€-
1,139€ range. Conversely, the AT strategy was cost-effective when the cost of genomic 
testing was taken to be greater than 1,891€.  The two strategies were found to be equivalent 
when the cost of genomic testing was taken to range between 1,139€ and 1,891€.  
Discussion 
Gene expression profiling could help to refine medical decision-making, but some questions 
about its economic impact need to be addressed before it can be used in routine clinical 
settings [27,28]. It is thus necessary to determine whether the use of genomic testing yields 
clinical benefits that justify the additional cost of testing all patients [21,29]. Although the 
cost of genomic testing is likely to be substantial, targeting treatments more selectively to 
those patients who are likely to benefit most might prevent therapeutic escalation and the 
corresponding costs.  
The present assessment of the potential impact of gene expression profiling on the cost of 
treatment and the survival of N+ breast cancer patients shows that the therapeutic strategy 
involving genomic testing is potentially cost-effective, depending on the cost of genomic 
testing. With costs lower than 2,090€ at the current drug prices (or less than 1,139€ when the 
price of docetaxel was assumed to drop by 30% once it has become a generic drug), treatment 
decisions based on gene expression profiling were found to be equally effective but 
significantly less costly than the strategy involving taxanes administered to all patients. 
Taking the cost of genomic testing to be in the 2,090€ to 2,919€ range (or in the 1,139€ to 
1,891€ range if the price of docetaxel decreases by 30%), the two strategies were found to 
have similar costs and effectiveness. It is worth noting that these costs (including tumour 
sample preparation and transportation) turned out to be lower than the price of the currently 
available genomic tests for breast cancer patients ($3,460 for Oncotype DX [30], for 
example).  
This analysis is subject to a number of limitations. First, the number of patients in our study 
sample was rather small, especially in the case of the poor prognosis group, in which the 
patients received an anthracyline plus taxane chemotherapy regimen. Another limitation is the 
existence of some uncertainty about the predictive value of gene expression profiling, as the 
clinical findings were based on retrospective data [24]. However, the latter limitation is 
common to many studies, and no direct evidence has been provided so far that gene 
expression profiling improves breast cancer patients‟ outcomes [31].  
A few studies have addressed the economic impact of gene expression profiling in the 
treatment of breast cancer patients. The results of these studies are not directly comparable 
with ours, however, mainly because of the differences between the therapeutic indications for 
gene expression profiling (N+ patients in our case, versus N- patients in previous studies). In 
the study by Hornberger et al., the cost-utility of using a 21-gene expression signature to 
reclassify patients initially defined as low- or high-risk patients according to the National 
Comprehensive Cancer Network (NCCN) clinical guidelines, was calculated as $31,452 per 
QALY gained, and the authors concluded that genomic testing has the potential to increase 
quality-adjusted survival and save costs [32]. These results were recently confirmed on a 
larger set of patients [33]. The study by Oestreicher et al. led to similar conclusions and 
suggested that performing gene expression profiling to identify the high-risk breast cancer 
patients who are likely to benefit most from adjuvant chemotherapy may yield net cost 
savings of $2,882 per patient [34]. All these studies were based on retrospective data, and 
their authors pointed out that the evidence about the economic outcomes was not very solid, 
since cost-effectiveness is difficult to assess until the clinical relevance of genomic testing for 
treatment decision-making purposes is confirmed. 
In view of the need expressed for cost-effectiveness analyses to inform decision-making about 
coverage/reimbursement, it is worth noting that cost-effectiveness findings do not actually 
solve this issue. Coverage/reimbursement decisions cannot be reduced to a matter of 
balancing health insurance budgets, since they are liable to affect the development of the 
newly developing pharmacogenomic sector: low pricing might create a negative incentive for 
developing new genomic tests, whereas high pricing might favour opportunities for rent 
seeking that would actually be financed by the health insurance subscribers. 
Another issue relating to coverage/reimbursement is that genomic testing and the drug 
targeted are complementary [35,36], which means that their joint use results in greater well-
being than the sum of those resulting from separate use. In particular, undergoing genomic 
testing generates very little if any well-being if the drug targeted is not available. Since higher 
value is usually attached to greater well-being, the question arises as to how increased well-
being should be priced. In view of the fact that genomic testing is intended to prevent over-
treatment and to reduce the magnitude and/or frequency of side-effects, well-being could be 
approached by assessing patients‟ quality of life. Although the issue of the monetary value of 
quality of life has been addressed by a few authors [37-39], these studies are still in the 
exploratory stage. 
The last point concerns the use of thresholds to classify patients depending on the results of 
genomic testing. In line with the premises of „personalized medicine‟, it seems somewhat 
contradictory to determine individual gene expression profiles and then express the results in 
terms of belonging to a group. Greater consistency could be achieved by expressing 
individual genomic test results in terms of the probability of responding to the drug targeted, 
for example. This would enable physicians and patients to make better informed decisions and 
inform the payers‟ decision-making about coverage, since the question would then arise as to 
how an „acceptable‟ probability of responding to drugs should be defined.  
Conclusion 
The introduction of new drugs in the adjuvant setting often yields rather low and 
heterogeneous benefits and generates morbidity and financial costs. The use of genomic tests 
targeting currently available drugs might therefore provide a useful means of preventing 
therapeutic escalation and the associated costs. The results of the present study suggest that 
genotyping breast cancer patients to guide medical decision-making about chemotherapy : 
restricting the administration of taxanes to those patients who are most likely to benefit from 
the treatment should decrease the cost of care. Further cost-effectiveness analyses based on 
prospectively collected data are now required to confirm these preliminary findings. Clinical 
trials could also provide insights on patients‟ quality of life and the acceptability of genomic 
testing to physicians and patients as a means of guiding decision-making about chemotherapy. 
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Table 1. Clinical characteristics of patients
included in the cost-effectiveness analysis
All patients Patients receiving Patients receiving
6 FEC 100 
1
3 FEC 100 + 3 Docetaxel 
2
(n=246) (n=128) (n=118)
Age (years)
mean ± sd 50 ± 8 50 ± 7.6 50 ± 8.3
range 29-65 31-65 29-65
Hormonal status
premenauposal 145 (59.4%) 77 (60.6%) 68 (58.1%)
menauposal 99 (40.6%) 50 (39.4%) 49 (41.9%)
ER status
negative 56 (22.8%) 33 (25.8%) 23 (19.5%)
positive 190 (77.2%) 95 (74.2%) 95 (80.5%)
PR status
negative 82 (33.3%) 41 (32.0%) 41 (34.7%)
positive 164 (66.6%) 87 (68.0%) 77 (65.3%)
SBR grade
SBR I 41 (16.9%) 20 (15.9%) 21 (17.9%)
SBR II 91 (37.4%) 46 (36.5%) 46 (39.0%)
SBR III 105 (43.2%) 58 (46.0%) 47 (39.8%)
non gradable 6 (2.5%) 2 (1.6%) 4 (3.4%)
Number of involved lymph nodes
mean ± sd 3.95±4.0 3.97 ± 3.9 3.80 ± 3.9
range 1-23 1-22 1-23
<= 3 151 (61.6%) 80 (62.5%) 71 (61.0%)
> 3 94 (38.4%) 48 (37.5%) 46 (39.0%)
Genomic testing
Good prognosis 197 (80%) 105 (82%) 92 (78%)
Poor prognosis 49 (20%) 23 (18%) 26 (22%)
1
 6 cycles of fluorouracil 500mg/m², epirubicin 100mg/m² and cyclophosphamide 500mg/m².
2
 3 cycles of fluorouracil 500mg/m², epirubicin 100mg/m² and cyclophosphamide 500mg/m² 
followed by 3 cycles of Docetaxel 100mg/m²,
ER: oestrogen receptor ; PR: progesterone receptor; SBR: Scarff Bloom Richardson  
 
 
 
 
Table 2. 5-year MFS* of good and poor prognosis patients, 
according to the treatment received.
All patients n=246 6 FEC 100
1
3FEC100 + 3Docetaxel
2
(n=128) (n=118)
Good prognosis (n=197) n=105 n=92
5-year MFS % survival 87.0% 84.9% 
95% IC [78.6% ; 92.3%] [75.3% ;91.0%]
Poor prognosis (n=49) n=23 n=26
5-year MFS % survival (95% IC) 60.9% 69.2%
95% IC [38.3% ; 77.4%]  [47.8% ; 83.3%]
* MFS: metastasis-free survival
1
 6 cycles of fluorouracil 500mg/m², epirubicin 100mg/m² and cyclophosphamide 500mg/m².
2 
6 cycles of fluorouracil 500mg/m², epirubicin 100mg/m² and cyclophosphamide 500mg/m² 
followed by 3 cycles of Docetaxel 100mg/m²,
Receiving 
 
 
Table 3. Treatment costs associated with strategies AT and GEN *
Strategies
According to genomic profile (n=131)
Costs average cost % total cost average cost % total cost
1. Therapeutic sequence only
3 573 € 28% 3 619 € 35,5%
1 160 € 9,1% 1 119 € 11,0%
5 417 € 42,7% 2 896 € 28,4%
5 015 € 39,5% 2 346 € 23,0%
including Docetaxel 4 081 € 32,2% 750 € 7,4%
402 € 3,2% 550 € 5,4%
2 538 € 20,0% 2 549 € 25,0%
12 688 € 10 183 €
[12 329 ; 13 047] [9825 ; 10543]
* cost of genomic testing not included in the total cost.  
Note1: 1€ = 1.3 US$
Note2: the treatment cost values include docetaxel priced ad a brand name drug.
3 FEC 100 + 3 Docetaxel (n=118)
Strategy GENStrategy AT
Surgery
Hospitalisation
(including toxicity)
Drugs
95% confidence intervall
Chemotherapy
        Other 
Laboratory
Total cost
 
 
 
Fig1. Decision tree: the two strategies compared 
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